Format

Send to

Choose Destination
Eur J Radiol. 2018 Oct;107:119-124. doi: 10.1016/j.ejrad.2018.08.027. Epub 2018 Aug 30.

Radiological prediction of positive circumferential resection margin in oesophageal cancer.

Author information

1
Division of Cancer & Genetics, School of Medicine, Cardiff University, UK. Electronic address: foleykg@cardiff.ac.uk.
2
Department of Histopathology, University Hospital of Wales, Cardiff, UK. Electronic address: Adam.Christian@wales.nhs.uk.
3
Department of Surgery, University Hospital of Wales, Cardiff, UK. Electronic address: Neil.Patel@wales.nhs.uk.
4
Department of Surgery, University Hospital of Wales, Cardiff, UK. Electronic address: Wyn.Lewis4@wales.nhs.uk.
5
Department of Radiology, University Hospital of Wales, Cardiff, UK. Electronic address: Ashley.Roberts@wales.nhs.uk.

Abstract

PURPOSE:

A positive circumferential resection margin (CRM) is regarded as a poor prognostic indicator in oesophageal cancer (OC) but its prediction can be challenging. MRI is used to predict a threatened CRM in rectal cancer but is not commonly performed in OC unlike PET/CT, which is now routinely used. Therefore, this study assessed the additional predictive value of PET-defined tumour variables compared with EUS and CT T-stage. The prognostic significance of CRM status was also assessed.

MATERIALS AND METHODS:

This retrospective study included 117 consecutive patients [median age 64.0 (range 24-78), 102 males, 110 adenocarcinomas, 6 squamous cell carcinoma (SCC), 1 neuro-endocrine] treated between 1st March 2012 and 31st July 2015. A binary logistic regression model tested 5 staging variables; EUS T-stage (≤T2 vs ≥ T3), CT T-stage (≤T2 vs ≥ T3), PET metabolic tumour length (MTL), PET metabolic tumour width (MTW) and the maximum standardised uptake value (SUVmax).

RESULTS:

The CRM was positive in 43.6%. Sixty-seven (57.3%) patients received neo-adjuvant chemotherapy (NACT), 31 patients (26.5%) underwent surgery alone and 19 patients (16.2%) had neo-adjuvant chemo-radiotherapy (NACRT). Median overall survival (OS) was 36.0 months (95% confidence interval (CI) 24.1-47.9) and the 2-year OS was 55.4%. A binary logistic regression model showed EUS ≥ T3 tumours were independently and significantly more likely to have a positive CRM than EUS ≤ T2 tumours (HR 5.188, 95% CI 1.265-21.273, p = 0.022). CT T-stage, PET MTL, PET MTW and SUVmax were not significantly associated with CRM status (p = 0.783, 0.852, 0.605 and 0.413, respectively). There was a significant difference in OS between CRM positive and negative groups (X2 4.920, df 1, p = 0.027).

CONCLUSION:

Advanced EUS T-stage is associated with a positive CRM, but PET-defined tumour variables are unlikely to provide additional predictive information. This study demonstrates the continued benefit of EUS as part of a multi-modality OC staging pathway.

KEYWORDS:

Endosonography; Esophageal neoplasms; Margins of excision; Positron-emission tomography

PMID:
30292255
DOI:
10.1016/j.ejrad.2018.08.027
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center